A Phase I Study of Crizotinib and Ganetespib (STA-9090) in ALK Positive Lung Cancers
Latest Information Update: 07 Nov 2021
At a glance
- Drugs Ganetespib (Primary) ; Crizotinib
- Indications Adenocarcinoma; Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- 28 Dec 2020 Status changed from active, no longer recruiting to completed.
- 25 Feb 2020 Planned End Date changed from 1 Apr 2020 to 1 Apr 2021.
- 25 Feb 2020 Planned primary completion date changed from 1 Apr 2020 to 1 Apr 2021.